Skip to main content

Table 1 Baseline characteristics of the ACS patients

From: Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China

Variables

patients (n = 341)

Age (years)

65.8 ± 10.9

Male, n (%)

253 (63.0)

Smoking, n (%)

67 (19.6)

Drinking, n (%)

6 (1.8)

Comorbidity

 

 Hypertension, n (%)

215 (63.0)

 Diabetes mellitus, n (%)

137 (40.1)

 Dyslipidemia, n (%)

82 (24.0)

 Angiographic follow-up (months)

34.2 ± 17.2

 Stent number (mm)

1.34 ± 0.65

Stent type

 

 Rapamycin, n (%)

275 (80.6)

 Everolimus, n (%)

24 (7.0)

 Zotamos, n (%)

28 (8.2)

Stent location

 

 LM, n (%)

15 (3.3)

 LAD, n (%)

191 (41.8)

 LCX, n (%)

98 (21.4)

RCA, n (%)

153 (33.5)

 ISR, n (%)

62/341 (18.2)

Average ISR time (month)

32.8 ± 26.8

ISR rate for vessel

 

 LM, n (%)

1/15 (6.7)

 LAD, n (%)

41/191 (21.5)

 LCX, n (%)

19/98 (19.4)

 RCA, n (%)

22/153 (14.4)

Medication

 

 Statin therapy, n (%)

321/341 (94.1)

 Antiplatelet therapy, n (%)

322/341 (94.4)

 Clopidogrel

136 (39.8)

 Ticagrelor

172 (50.4)

 Aspirin

285 (83.5)

 Oral anticoagulation, n (%)

1/341 (0.3)

 ACEI/ARB, n (%)

298/341 (87.3)

  1. LM left main coronary artery, LAD left anterior descending coronary artery, LCX left circumflex artery coronary artery, RCA right coronary artery, ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker